Clinical Trials, U.S.: Parkinson’s Disease

International Stem Cell Corporation, a California biotechnology company currently developing biomedical products and new stem cell therapies, announced on April 29, 2014, that some behavioral progress has been observed over a six-month period in the preclinical nonhuman primate (NHP) study of Parkinson’s disease (PD), which includes 18 primates, all exposed to neurotoxin MPTP. These results are particularly remarkable and promising as they mean, for patients, greater decrease in the severity of their symptoms. The detailed data will be introduced at the upcoming 66th American Academy of Neurology Annual Meeting in Philadelphia.

Parkinson’s disease is a degenerative condition of the central nervous system (CNS), in which motor symptoms are caused by the death of cells located in the midbrain that are responsible for the production of dopamine. ...